Navinci has developed several in situ Proximity Ligation Assays, providing deep biological knowledge about the signaling pathways of PD1 and PD-L1.
The first assay available to order is:
PD1 PD-L1 signaling has proven significant in cancer progression, and therapies with immune checkpoint inhibitors have revolutionized cancer treatment efficacy. Despite the recent success, many patients do not benefit from these therapies, and predictive biomarkers improving patient stratification are needed. PD-L1 IHC is the most commonly used biomarker, but the correlation between PD-L1 expression levels and PD1/PD-L1 interaction is not always linear.
PD1 activation is an essential step in the signaling pathway, yet phosphorylation of PD1 in situ is not well studied, mainly due to the lack of specific methods. Navinci is launching the first commercial Proximity Ligation Assay to precisely detect phosphorylated PD1.
Read more: https://navinci.se/product/naveni-py-pd1/
- Naveni PD1/PD-L1 (protein-protein interaction),
Contact us if you want to know more!